PACIRA BIOSCIENCES INC (PCRX) Stock Institutional Trading Activity


PACIRA BIOSCIENCES INC (PCRX) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q4 2025), investors with some of the largest reported share count changes include Renaissance Technologies LLC and First Eagle U.S. Value. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q4 2025Renaissance Technologies LLCSell-254,2001,884,001$48,757,946
Q3 2025Renaissance Technologies LLCSell-257,4002,138,201$55,101,440
Q2 2025Renaissance Technologies LLCBuy155,0002,395,601$57,254,864
Q1 2025Renaissance Technologies LLCBuy248,0002,240,601$55,678,935
Q4 2024Renaissance Technologies LLCBuy13,6041,992,601$37,540,603
Q3 2024Renaissance Technologies LLCSell-87,2001,978,997$29,783,905
Q2 2024Renaissance Technologies LLCBuy184,0002,066,197$59,113,896
Q1 2024Renaissance Technologies LLCBuy165,5001,882,197$54,998
Q4 2023Renaissance Technologies LLCBuy102,7001,716,697$57,921
Q4 2023First Eagle U.S. ValueSell-104,551103,081$3,477,953
Q3 2023Renaissance Technologies LLCBuy39,3001,613,997$49,517
Q3 2023First Eagle U.S. ValueSell-36,640207,632$6,370,150
Q2 2023Renaissance Technologies LLCBuy15,8001,574,697$63,098
Q2 2023First Eagle U.S. ValueBuy67,847244,272$9,787,979
Q1 2023Renaissance Technologies LLCSell-28,2001,558,897$63,619
Q1 2023First Eagle U.S. ValueBuy93,412176,425$7,199,905
Q4 2022Renaissance Technologies LLCSell-166,4001,587,097$61,278
Q4 2022First Eagle U.S. ValueBuy4,48283,013$3,205,132
Q3 2022First Eagle U.S. ValueBuy8,70678,531$4,177
Q3 2022Renaissance Technologies LLCSell-212,0001,753,497$93,269
Q2 2022First Eagle U.S. ValueBuy22,10469,825$4,071
Q2 2022Renaissance Technologies LLCBuy104,5001,965,497$114,588
Q1 2022First Eagle U.S. ValueBuy22,88947,721$3,642
Q1 2022Renaissance Technologies LLCBuy11,8001,860,997$142,031
Q4 2021First Eagle U.S. ValueBuy24,83224,832$1,494
Q4 2021Renaissance Technologies LLCSell-119,6001,849,197$111,266
Q3 2021Renaissance Technologies LLCSell-91,5301,968,797$110,253
Q2 2021Renaissance Technologies LLCSell-254,4702,060,327$125,021
Q1 2021Renaissance Technologies LLCSell-310,2622,314,797$162,244
Q4 2020Renaissance Technologies LLCSell-155,0382,625,059$157,084

Frequently asked questions about PCRX activity

  • Which institutional owners are buying PCRX?

    Institutional owners buying PCRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in PCRX activity?

    "Buy" means an investor increased their reported position in PCRX compared to the prior reporting period. This reflects growing exposure to PACIRA BIOSCIENCES INC (PCRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in PCRX increasing?

    Institutional interest in PCRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.